MYOSITIS
Clinical trials for MYOSITIS explained in plain language.
Never miss a new study
Get alerted when new MYOSITIS trials appear
Sign up with your email to follow new studies for MYOSITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for rare muscle disease in early trial
Disease control OngoingThis study tests an investigational drug called nipocalimab in 36 adults with active myositis, a condition causing muscle inflammation and weakness. Participants receive either nipocalimab or a placebo to see if the drug improves muscle strength and function while allowing lower …
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 10:05 UTC
-
Promising psoriasis drug fails to launch in muscle disease trial
Disease control TerminatedThis study planned to test deucravacitinib, a pill already approved for psoriasis, in adults with dermatomyositis or juvenile dermatomyositis that did not respond to standard treatments. The goal was to see if the drug could improve muscle and skin symptoms. However, the study wa…
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated May 26, 2026 09:55 UTC
-
New drug shows promise for Long-Term myositis control
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called efgartigimod for adults with a group of muscle diseases called myositis. People who already took part in a previous study of this drug can join. They will receive the drug for up to 51 months and then be followed for 56 da…
Matched conditions: MYOSITIS
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Early IVIg boost may tame muscle disease before it disables
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis leads to faster improvement than steroids alone. Myositis is a group of rare diseases that cause muscle inflammation and weakness. The trial includes 44 adults diagno…
Matched conditions: MYOSITIS
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New drug hope for rare muscle disease
Disease control OngoingThis study tests a new medicine called empasiprubart against a placebo in adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. About 3 participants will receive the drug or placebo for 25 weeks, then be followed for safety over a year. The goal is …
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Pregnancy study for rare diseases cancelled before it began
Knowledge-focused TerminatedThis study planned to follow women with rare autoimmune diseases (like lupus or arthritis) through pregnancy to learn about complications and improve care. It was withdrawn before any participants enrolled, so no results are available. The goal was to gather information to help d…
Matched conditions: MYOSITIS
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 26, 2026 10:07 UTC